Intravitreal bevacizumab for uveitic choroidal neovascularization.
OBJECTIVE
To report 5 cases of inflammatory choroidal neovascularization (CNV) that were treated with intravitreal bevacizumab.


METHODS
Six eyes of 5 patients with uveitic CNV were treated with 2.5 mg/0.1 mL of intravitreal bevacizumab. Main outcome measures were the changes in BCVA and reduction in the size of the CNV.


RESULTS
The mean follow-up time was 15.3 months. The mean intravitreal injections administered were 2.7. All patients showed a reduction in the size of the CNV with improvement in BCVA in 60% of cases at the last follow-up.


CONCLUSIONS
Intravitreal bevacizumab may provide an additional strategy in the management of inflammatory CNV.
Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts 02142, USA.
Priyanka P
PP
Doctor
Pooja
P
Bhat
Reema
R
Sayed
C Stephen
CS
Foster
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D005139:Eyeglasses; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014605:Uveitis / Q000150:complications*; D014792:Visual Acuity; D014822:Vitreous Body; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab